Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004043 · ClinicalTrials.gov registry record · Phase 2
Calcitriol in Treating Patients With a Rising PSA Level Following Treatment for Prostate Cancer
A Phase 2 study, sponsored by OHSU Knight Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT00004043 is a Phase 2 study that has completed, run by OHSU Knight Cancer Institute. The registered enrollment target is 25 participants.
The verdict
NCT00004043, a Phase 2 study, has completed, sponsored by OHSU Knight Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
RATIONALE: Calcitriol, a form of vitamin D, may be able to prevent or slow the growth of prostate cancer cells. PURPOSE: Phase II trial to study the effectiveness of calcitriol in treating patients who have a rising PSA level following previous treatment for prostate cancer.
Interventions
- DIETARY_SUPPLEMENT calcitriol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 1999-02 |
| Est. Completion | 2003-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00004043
The ClinicalTrials.gov registry entry for NCT00004043 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is OHSU Knight Cancer Institute, which has 211 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which calcitriol is the first listed.
NCT00004043 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00004043 about?
NCT00004043 is a clinical study titled "Calcitriol in Treating Patients With a Rising PSA Level Following Treatment for Prostate Cancer". RATIONALE: Calcitriol, a form of vitamin D, may be able to prevent or slow the growth of prostate cancer cells. PURPOSE: Phase II trial to study the effectiveness of calcitriol in treating patients who have a rising PSA level following previous treatment for prostate cancer.
What is the current status of trial NCT00004043?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 1999-02. Estimated completion is 2003-03.
What interventions are being tested in trial NCT00004043?
The interventions under investigation include: calcitriol (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00004043?
This trial is sponsored by OHSU Knight Cancer Institute, which has 211 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.